TOKYO, March 20 (Reuters) - Astellas Pharma Inc., Japan’s third-largest drug maker, said on Tuesday that U.S. authorities have said they could not yet approve the simultaneous use of its mainstay drug Prograf and another medicine for kidney transplant patients.
